New Class of Drug Modalities: Directed Evolution of a De Novo Designed Helix–Loop–Helix Peptide to Bind VEGF for Tumor Growth Inhibition-Reference-Cited by-同舟云学术

New Class of Drug Modalities: Directed Evolution of a De Novo Designed Helix–Loop–Helix Peptide to Bind VEGF for Tumor Growth Inhibition

Published:2022-02-18 Issue:3 Volume:17 Page:647-653
ISSN:1554-8929
Container-title:ACS Chemical Biology
language:en
Short-container-title:ACS Chem. Biol.

Author:

Michigami Masataka¹,Ramanayake Mudiyanselage Tharanga M. R.²,Suzuki Miho¹,Ishizako Hirotsugu¹,Notsu Kunpei¹,Sugiura Kikuya²,Fujii Ikuo¹^ORCID

Affiliation:

1. Department of Biological Science, Graduate School of Science, Osaka Prefecture University, 1-1 Gakuen-cho, Naka-ku, Sakai, Osaka 599-8531, Japan

2. Department of Veterinary Science, Graduate School of Life and Environmental Science, Osaka Prefecture University, 1-58 Rinku-oraikita, Izumisano, Osaka 598-8531, Japan

Funder

Japan Agency for Medical Research and Development

Publisher

American Chemical Society (ACS)

Subject

Molecular Medicine,General Medicine,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acschembio.1c00940

Reference22 articles.

1. Antibodies to watch in 2020

2. Top companies and drugs by sales in 2019

3. Engineering novel binding proteins from nonimmunoglobulin domains

4. A novel strategy to design binding molecules harnessing the modular nature of repeat proteins

5. Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bohemian Rhapsody of Future Drug Delivery Systems: Rational Changes Necessary for the Next Revolution;Molecular Pharmaceutics;2024-07-12